Home
Live Updates
Fresenius Kabi Announces Launch Of TYENNE, A Tocilizumab Biosimilar Referencing ACTEMRA - Life Sciences, Biotechnology & Nanotechnology : comparemela.com
Fresenius Kabi Announces Launch Of TYENNE, A Tocilizumab Biosimilar Referencing ACTEMRA - Life Sciences, Biotechnology & Nanotechnology
On April 15, 2024, Fresenius Kabi announced the U.S. launch of its ACTEMRA biosimilar, TYENNE (tocilizumab-aazg) as an intravenous formulation.
Related Keywords
Netherlands ,
California ,
United States ,
Carlton ,
Holland ,
Stephen Page ,
Gina Bertolini ,
Michael Esquivel ,
Halle Tecco ,
Akin Gump Strauss Hauer Feld ,
Us Department Of Justice ,
Holland Knight ,
Life Sciences ,
Proskauer Rose ,
Drug Administration ,
California Office Of Health Care Access ,
Goodwin Procter ,
California Health Care Quality ,
Human Service Office ,
Inspector General ,
California Office ,
Health Care Access ,
Affordability Act ,
Sarah Staples Carlton ,
Mondaq ,
Fresenius Kabi Announces Launch Of Tyenne ,
A Tocilizumab Biosimilar Referencing Actemra ,
Food ,
Drugs ,
Healthcare ,
Iotechnology Amp Nanotechnology ,
,
comparemela.com © 2020. All Rights Reserved.